



T: 0131-244-2528
E: irene.fazakerley@gov.scot

IMMEDIATE MESSAGE TO:

1. Directors of Pharmacy
2. Medical Directors NHS Boards

3 October 2024

Dear Healthcare Professional,

**DRUG ALERT CLASS 3 DRUG ALERT 46 2024 – CLASS 3 MEDICINES RECALL –
ACTION WITH 5 DAYS – GLENMARK PHARMACEUTICALS EUROPE LTD –
CYANOCOBALAMIN 50MCG TABLETS**

Please see drug alert for onward transmission as below

Could all Directors of Pharmacy please forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Primary Care Pharmacists

Please could Medical Directors arrange to forward this alert on to:-

- General Practitioners
- Accident & Emergency Departments
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

IRENE FAZAKERLEY
Medicines Policy Team





Medicines & Healthcare products
Regulatory Agency

MEDICINES RECALL

CLASS 3 MEDICINES RECALL

Action Within 5 Days
Pharmacy/Wholesaler Level Recall

Date: 03 October 2024

EL (24)A/46

Our Ref: DMRC-31522269

Dear Healthcare Professional,

Glenmark Pharmaceuticals Europe Ltd

Cyanocobalamin 50 mcg Tablets

PL 25258/0369

SNOMED Code N/A

Batch No	Expiry Date	Pack Size	First Distributed
17231378A	30-Nov-2024	50	01-Oct-2023
17231510A	30-Nov-2024	50	14-Mar-2024
17231511A	31-Dec-2024	50	17-Apr-2024

Active Pharmaceutical Ingredient: cyanocobalamin

Brief description of the problem

Glenmark Pharmaceuticals Europe Ltd is recalling the affected batches as a precautionary measure due to out of specification results for unknown impurities during routine stability testing and additional re-testing.

Advice for healthcare professionals

Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

Advice for patients

No action is required by patients as this is a Pharmacy and Wholesaler level recall. Patients should continue to take medicines from these batches as prescribed by your healthcare professional.

Patients who experience adverse reactions or have any questions about the medication, should seek medical attention. Any suspected adverse reactions should also be reported via the [MHRA Yellow Card scheme](#).

Further Information

For medical information enquiries please use the following options by phone +44 8004 580 383 or email medical_information@glenmarkpharma.com

For stock control enquiries please email orders.uk@glenmarkpharma.com



Medicines & Healthcare products Regulatory Agency

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574
DMRC@mhra.gov.uk